1. Home >
  2. M&A >
  3. Divestiture >
  4. France >
  5. Juvisé Pharmaceuticals Acquires Juvisé Pharmaceuticals - Arimidex & Casodex

M&A Deal Summary

Juvisé Pharmaceuticals Acquires Juvisé Pharmaceuticals - Arimidex & Casodex

On December 20, 2019, Juvisé Pharmaceuticals acquired life science company Juvisé Pharmaceuticals - Arimidex & Casodex from AstraZeneca

Acquisition Highlights
  • This is Juvisé Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Juvisé Pharmaceuticals’ 1st transaction in France.

M&A Deal Summary
Date 2019-12-20
Target Juvisé Pharmaceuticals - Arimidex & Casodex
Sector Life Science
Buyer(s) Juvisé Pharmaceuticals
Sellers(s) AstraZeneca
Deal Type Divestiture

Target

Juvisé Pharmaceuticals - Arimidex & Casodex

Villeurbanne, France
Juvisé Pharmaceuticals - Arimidex & Casodex business Arimidex is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and the treatment of advanced breast cancer in postmenopausal women with disease progression, following tamoxifen therapy. Casodex® (bicalutamide) is an androgen-receptor inhibitor, indicated for use in combination therapy with a luteinising hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Juvisé Pharmaceuticals

Villeurbanne, France
Category Company
Sector Life Science
DESCRIPTION

Juvisé Pharmaceuticals is an international pharmaceutical company, specialized in manufacturing and commercializing ethical original drugs with high medical value for patients suffering from cardiovascular, oncology or neuropsychiatric diseases.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: France M&A 1 of 1
Year: 2019 M&A 1 of 1

Seller(S) 1

SELLER

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 54.1B USD (2024)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 11 of 11
Sector: Life Science M&A 7 of 7
Type: Divestiture M&A Deals 11 of 11
Country: France M&A 1 of 1
Year: 2019 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-06 AstraZeneca - Alvesco Omnaris and Zetonna Business

London, United Kingdom

AstraZeneca Plc - Alvesco, Omnaris and Zetonna Business used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines.

Sell $350M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-17 Dogma s Oral PCSK9 Inhibitor Program

Boxford, Massachusetts, United States

Dogma's Oral PCSK9 Inhibitor Program is a protein that regulates the level of low-density lipoprotein (LDL) or ‘bad’ cholesterol in the blood. Increased activity of PCSK9 is associated with high LDL cholesterol.

Buy -
Mergr

Solution for

Product

Company

Legal